K(
Therapeutic Areas
VaxCyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VAX-31 | Invasive Pneumococcal Disease (IPD) & Pneumonia in Adults | Phase 3 |
| VAX-24 | Invasive Pneumococcal Disease (IPD) in Infants | Phase 2 |
| VAX-XL | Invasive Pneumococcal Disease (IPD) | Preclinical |
| VAX-A1 | Group A Streptococcus (GAS) Infection | Preclinical |
| VAX-GI | Shigella Infection (Shigellosis) | Preclinical |
Leadership Team at VaxCyte
GP
Grant Pickering
Chief Executive Officer, Director and Co-Founder
JF
Jeff Fairman
Senior Vice President, Research and Co-Founder
AG
Andrew Guggenhime
Chief Financial Officer
J(
James (Jim) Wassil
Chief Operating Officer
B(
Brady (Brent) Lyon
Chief Medical Officer
MB
Michelle Berrey
Board Member
MK
Michael Kamarck
Board Member